{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.1444.5.201","meta":{"versionId":"6","lastUpdated":"2020-09-02T01:00:24.000-04:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.201","version":"20200902","name":"Epirubicin","status":"active","date":"2020-09-02T01:00:24-04:00","publisher":"American Society of Clinical Oncology Steward","compose":{"include":[{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.200"]}]},"expansion":{"identifier":"urn:uuid:cfe5e3e0-45cc-4282-8bb6-8416ca59635d","timestamp":"2022-06-10T07:26:46-04:00","total":2,"offset":0,"parameter":[{"name":"count","valueInteger":1000},{"name":"offset","valueInteger":0}],"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"1732182","display":"25 ML epirubicin hydrochloride 2 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"1732186","display":"100 ML epirubicin hydrochloride 2 MG/ML Injection"}]}}